Company intelligence / Profile preview

Bloom

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

BL-001, Bloom's lead program, demonstrated statistically significant, durable weight loss in overweight individuals in a Phase 1 trial and was safe and tolerable; entering Phase 2 for obesity and Dravet syndrome[1].

Therapeutic areas: NeurologyEndocrinologyMetabolic Disorders
Modalities: Live biotherapeutic product therapyMicrobial therapySynthetic biology-based therapy
Industry: Biotech

Partnerships

Not specifically disclosed; company states interest in collaborators and industry partnerships[1].

Beyond the preview

Go deeper on Bloom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bloom.

Explore the full profile